

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



絲路投資

Asia Pacific Silk Road Investment Company Limited

亞太絲路投資有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Asia Pacific Silk Road Investment Company Limited (the “**Company**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 8 January 2021, Blooming Faith Development Limited, a wholly-owned subsidiary of the Company, (the “**Purchaser**”) entered into an agreement for the acquisition of medical testing centres (the “**Acquisition Agreement**”) with Zhong Ji 1 International Medical Group (Hong Kong) Limited. (the “**Vendor**”). Pursuant to the Acquisition Agreement, the Vendor has agreed to transfer the Irving Weissman Advanced Medical Testing Center and the Asian Advanced Medical Testing Center as well as their devices and equipment to the Purchaser for a price of one Hong Kong dollar.

Responsibilities and Obligations

1. The Vendor is responsible for transferring all the devices in as well as the qualifications and certificates of the two medical testing centres to the Purchaser.
2. Following the signing of the agreement, the Vendor shall facilitate the signing of the respective lease agreements by the Purchaser and the landlords for the usage fee of the premises at which the two existing medical testing centres are located.
3. Apart from the existing devices, the Purchaser shall be responsible for purchasing new devices according to the actual business needs of the medical testing centres.

4. After the signing of the Acquisition Agreement and the on-site transfer, the Purchaser shall be responsible for recruiting allied testing professionals and the Vendor has agreed to provide corresponding technical training and support free of charge.
5. The Vendor shall ensure that after the completion of the transfer of the two medical testing centres, it will no longer engage in any testing business of the same type.

The particulars of the businesses of the two medical testing centres are as follows:

Irving Weissman Advanced Medical Testing Center

1. Circulating tumor cell (CTC) blood test: early cancer detection and screening using an advanced and non-invasive laboratory test.
2. Cell culture platform: culture of cancer cell line K562 and detection of NK cell cytotoxicity using the Herasafe 2030i Class II A2 Biosafety Cabinet.
3. T cell detection platform: for T cell subsets, in addition to using CD4 and CD8 to analyse helper T cells (CD3 + CD4 +) and killer T cells (CD3 + CD8 +), the functional activation status of T cells can also be further analysed.
4. Nature killer cell detection platform: NK cells play an important role in immune tolerance and immune stability, including interactions with different immune cells, secretion of various cytokine, and inhibition of receptors.
5. Biological age detection platform: detection of telomeres in nucleated haematopoietic cells using a fluorescein-conjugated peptide nucleic acid (PNA) probe, telomere length measurement and biological age estimation.
6. Endotoxin quantitation platform: detection of gram-negative bacterial endotoxins using the Varioskan™ LUX multimode microplate reader.
7. Mycoplasma detection platform: mycoplasma detection using the Varioskan™ LUX multimode microplate reader.
8. Automatic blood testing platform: full complete blood count (CBC) + 5-part results using the Mindray BC-5000 Auto Hematology Analyzer.
9. Coagulation function testing platform: test of platelet count and MPV (mean platelet volume) using the Mindray BC-5000 Auto Hematology Analyzer.
10. Lipid profile testing platform: test of total cholesterol (TC), HDL-cholesterol (HDL-C), triglycerides (TG), apolipoprotein A1 (Apo-A1) and apolipoprotein B (Apo-B) using the Mindray BS230 Auto Chemistry Analyzer.

Asian Advanced Medical Testing Center

1. Auto-immue testing platform: detection of TGA (anti-Tg), TRAb, TMA, anti-TPO, ICA, IAA (anti insulin), anti dsDNA, ANA, ENA, anti-SM, anti-ribosomal-P, anti-Scl-70, anti-CENP-B, anti-Jo-1, anti-M2, anti-histone, anti-RNP and anti-SSB using the Snibe Maglumi 800 CLIA Analyzer.
2. Infectious disease detection platform: detection of HBsAg, anti-HBs, HBeAg, anti-Hbe, anti-HBc, anti-HCV, syphilis, Chagas, HTLV I/II, anti-HAV, HAV IgM, HIV Ab and HIV p24 Ag using the Snibe Maglumi 800 CLIA Analyzer.
3. Thyroid disease detection platform: detection of TSH (3rd Generation), T4, T3, FT4, FT3Tg (Thyroglobulin), TGA (anti-Tg), TRAb, TMA, anti-TPO, Rev T3 and intact PTH using the Snibe Maglumi 800 CLIA Analyzer.
4. Liver index testing platform: detection of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transferase (GGT), alkaline phosphatase (ALP), albumin (ALB), total protein (TP), prealbumin (PA), total bile acids (TBA), cholinesterase (CHE), direct bilirubin-DSA Method (DBI-D), total bilirubin-DSA Method (TBI-D), direct bilirubin-VOX Method (DBI-V), total bilirubin-VOX Method (TBI-V) and α -L-fucosidase (AFU) using the Mindray BS230 Auto Chemistry Analyzer.
5. Kidney index testing platform: detection of Creatinine-Modified Jaffe Method (CREA-J)/Creatinine-Sarcosine Oxidase Method (CREA-S), urea (UREA), uric acid (UA), microalbumin (MALB), cystatin C (Cys-C), β 2-microglobulin (β 2-MG), retinol binding protein (RBP) and carbon dioxide (CO₂) index using the Mindray BS230 Auto Chemistry Analyzer.
6. Cardiac panel detection platform: detection of creatine kinase (CK), creatine kinase-MB (CK-MB), α -hydroxybutyrate dehydrogenase (α -HBDH), homocysteine (HCY), high sensitivity C-reaction protein (HS-CRP), myoglobin (MYO), D-dimer and lactate dehydrogenase (LDH) using the Mindray BS230 Auto Chemistry Analyzer.
7. Male reproductive health testing platform: test of indicators of male reproductive health using the Snibe Maglumi 800 CLIA Analyzer.
8. Female reproductive health testing platform: test of indicators of female reproductive health using the Snibe Maglumi 800 CLIA Analyzer.
9. Cancer markers detection platform: test of cancer markers using the Snibe Maglumi 800 CLIA Analyzer.

Reasons for and Benefits of the Transaction

The Board believes that the acquisition of two medical testing centres as well as their devices and equipment enables the Group to expand into the medical testing business and generate stable income in the long run, which are in the interests of the Company and the shareholders as a whole.

By Order of the Board
Asia Pacific Silk Road Investment Company Limited
Yan Li
Chairman

Hong Kong, 8 January 2021

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yeung Siu Keung
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Chan Wai Dune
Mr. Mak Ping Leung (alias Mr. Mak Wah Cheung)
Mr. To Langa Samuelson

Non-executive Directors

Ms. Yu Yang
Ms. Choi Ngai Wah

In case of any inconsistency, the English version of this announcement shall prevail over the Chinese text.